PSC
PETX

Piper Sandler & Co’s Aratana Therapeutics, Inc. PETX Stock Holding History

Piper Sandler & Co’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,934
Closed -$79K – 130
2015
Q1 		$79K Buy
+4,934
New +$87.8K 0.03% 104

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Piper Sandler & Co's PETX Position: Q2 2015 in Review

Piper Sandler & Co sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2015, closing a stake of 4,934 shares — an estimated $79K sold.

Piper Sandler & Co first reported a position in PETX in Q1 2015 and held it in 1 quarter. The position peaked at $79K in Q1 2015. 92 funds tracked by Wall St. Rank hold PETX as of Q2 2015.

  • Piper Sandler & Co reported no remaining Aratana Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 4,934 Aratana Therapeutics, Inc. shares in Q2 2015, an estimated $79K.
  • Piper Sandler & Co first reported a position in Aratana Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Piper Sandler & Co's Aratana Therapeutics, Inc. position peaked at $79K in Q1 2015.
  • 92 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2015.

Based on Piper Sandler & Co's 13F filing for Q2 2015, filed 14 Aug 2015.